---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-26-000011"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:57:03.672072+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics Q1 net loss $13.5M; sells JZP898 to Jazz and repays K2 debt

## Summary
- Cash and cash equivalents $46.5M as of March 31, 2026, vs $57.1M at Dec 31, 2025.
- Net loss of $13.5M for Q1 2026, improved from $18.1M loss in Q1 2025.
- R&D expenses $8.2M (down from $13.1M YoY); G&A expenses $5.1M (up from $4.9M).
- Entered asset purchase agreement with Jazz Pharmaceuticals for JZP898 (IFNα program); repaid all K2 loan obligations as of May 6, 2026.
- Company continues to evaluate strategic alternatives with Piper Sandler; cash runway guidance to be updated.

## SEC filing metadata
- accession: 0001785530-26-000011
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553026000011/0001785530-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553026000011/howl-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-26-000011
- JSON: https://secwatch.observer/filing/0001785530-26-000011.json
- Plain text: https://secwatch.observer/filing/0001785530-26-000011.txt

## Source-grounded claims
- claim_id: 4f6ac944054104e6fb06b906f808858f6f454274
  claim: Werewolf Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $13.5 million for the first quarter of 2026.
  evidence_excerpt: Net loss was $13.5 million for the first quarter of 2026, compared to $18.1 million for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000178553026000011/0001785530-26-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.